ISRCTN17097163已完成3 期
Cerebrolysin trial in neuroprotection and neurorecovery after traumatic brain injury
EN: The foundation for the study of neuroscience and reuroregeneration (RO: Fundatia pentru Studiul Nanoneurostiintelor si Neuroregenerarii)0 个研究点目标入组 142 人开始时间: 2018年12月21日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 142
研究概览
简要总结
2020 Results article in https://www.ncbi.nlm.nih.gov/pubmed/31897941 results (added 28/02/2020)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Diagnosis of TBI and a GCS score of 7-12 at the time of hospital admission. Pre-hospital intubation/sedation/paralysis is accepted if the GCS score has been assessed before intubation/sedation/paralyses by trained personnel.
- •2. Pre-treatment GCS score of 7-12. If intubation/sedation/paralysis occurs after hospital admission, the pre-treatment GCS score has been assessed before intubation/sedation/paralyses.
- •3. Isolated TBI only (abbreviated injury score (AIS) in other body regions of =2)
- •4. CT (Marshal classification) I to VI (from diffuse injury to non-evacuated mass lesion)
- •5. Pre-Trauma Karnofsky Index = 100. If no corresponding information is available before the start of treatment (e.g., patient is unconscious or not able to communicate) and no information is retrieved within 24 hours after the start of treatment, the patient stays in the study. If no information is available before the start of treatment and a violation of the Karnofsky Index is detected within 24 hours after the start of treatment, the patient is withdrawn from the study, and the treatment medication is stopped.
- •6. Aged 18-80 years
- •7. Able to provide written informed consent to enrollment
- •8. Willing and able to comply with the protocol requirements for the duration of the study
- •9. Women of child-bearing potential with a negative urine pregnancy test who are willing to practice an acceptable method of birth control
- •10. Time to needle for study medication should be within 4 hours
- •11. Patients were able to speak, read and write before the accident. If no corresponding information is available before the start of treatment (e.g., patient is unconscious or not able to communicate) and if no information is retrieved within 24 hours after the start of treatment, the patient should remain in the study. If no information is available before the start of treatment and if a violation of this inclusion criterion is detected within 24 hours after the start of treatment, the patient should be withdrawn from the study, and the treatment medication should be stopped.
排除标准
- •1. Patients with polytrauma (AIS score in other body regions of >2)
- •2. Patients with spinal cord injury
- •3. History of intracranial interventionor ischemic or hemorrhagic stroke
- •4. Existence of psychiatric disorders or neurodegenerative diseases
- •5. Patients who in the investigator’s opinion would not comply with study procedures
- •6. Patients with a history of epileptic seizure
- •7. Use of concomitant neuroprotective treatment or cholinesterase inhibitors for previous cognitive treatment
- •8. Persons who are under chronic treatment with cortisone, Ca+-channel blockers, antidepressants, antipsychotic drugs or nootropic molecules
- •9. Significant or unstable medical, systemic or logistical condition that affects the subject’s ability to give informed consent or to complete the study procedures
研究者
相似试验
已完成
4 期
Can Cerebrolysin improve aphasia after ischemic stroke?Patients with Broca or mixed non-fluent aphasia post ischemic stroke with onset 3-5 days prior to inclusionCirculatory SystemBroca or mixed non-fluent aphasia following ischemic strokeISRCTN54581790The foundation for the study of neuroscience and neuroregeneration (SSNN)132
已完成
3 期
Cerebrolysin to prevent intracranial bleeding after intravenous thrombolysis (blood clot) in patients with ischemic strokeIschemic strokeCirculatory SystemISRCTN87656744State Autonomous Institution of Health Interregional Clinical Diagnostic Center341
终止
4 期
The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and NeurorecoveryTraumatic Brain InjuryNCT01606111Ever Neuro Pharma GmbH46
已完成
2 期
Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's DiseaseAlzheimer DiseaseNCT00911807Ever Neuro Pharma GmbH217
招募中
2 期
Cerebrolysin in CADASIL2024-513828-42-00Ever Neuro Pharma GmbH30